Competition & Peer Data API & CSV Delivery Connect to AI Assistant via MCP

Satellos Bioscience Inc's Competitiveness

Name: Satellos Bioscience Inc Competitors and Peer Comparison
Creator: CSIMarket
License: https://csimarket.com/help/terms-of-use

A competitive positioning analysis and financial ratio benchmarking of Satellos Bioscience Inc (MSLE) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.

Peer Data As of Q4 2025

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/MSLE/competitors                    

                        https://api.csimarket.com/api/v1/companies/MSLE/relationships                    

                        https://api.csimarket.com/api/v1/companies/MSLE/similar                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AI Integration via MCP

Connect Claude, ChatGPT, or any MCP-compatible AI assistant directly to this data.

Satellos Bioscience Inc's Competitor Quality Breadth

Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).

Entity	Profitable	Expanding	Above Industry Growth	Distressed
Satellos Bioscience Inc	-	-	-	-
Similar-Size Competitors (10)

Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.

MSLE Stock Performance relative to its Competitors

MSLE Competitors (weighted) Percent change over the selected range

Satellos Bioscience Inc's Share Price Performance vs Peer Groups

Trailing 12-month total share price return, and the share of each group that outperformed the U.S.A. 500 over the same period. Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC.

Similar-Size
(3 of 9)

Entity	TTM Share Price Return (group: median)	vs U.S.A. 500
Satellos Bioscience Inc	43.70 %	Outperformed
Competitors combined (0)	40.4%	63.2%
High-Confidence Competitors (0)	40.4%	63.2%
Similar-Size Competitors (9)	40.4%	63.2%
Similar Growth & Profitability (0)	40.4%	63.2%

Peer Group Share Price Returns

TTM share price return and U.S.A. 500 outperformance for Satellos Bioscience Inc's competitor groups requires a Commercial License.

Unlock Commercial Access

Source: CSIMarket API (daily market-structure computation). Outperformance is trailing-12-month total return vs the U.S.A. 500 over the same window, not risk-adjusted.

MSLE Stock Performance relative to Similar-Size Competitors

MSLE Similar-Size Competitors (equal-weighted, 10) Percent change over the selected range

Satellos Bioscience Inc's Comment on Competition and Industry Peers

The biotechnology industry in which the Company operates is highly competitive. The Company faces competition from other firms, including Satellos, some of which possess greater financial resources, retail, formulation, research, processing, production, sales, marketing experience, personnel, and resources. Competitors may develop products and strategies that are equally or more effective or economical, potentially rendering the Company's business, products, and strategies less effective or obsolete. If a competitor obtains FDA approval for the same drug and indication, the competitor's exclusivity could prevent approval of the Company's product candidate for seven years unless the Company's product demonstrates clinical superiority. Orphan Drug Designation exclusivity may also be lost under certain conditions. On August 8, 2024, Satellos announced that the FDA granted Orphan Drug Designation to SAT-3247 for the treatment of Duchenne muscular dystrophy.

Competitor data is not yet available for Satellos Bioscience Inc.